Neuralink, the neurotechnology venture founded by Elon Musk, has successfully implanted its proprietary brain-chip device in a second human patient. This development comes as the company navigates ongoing federal inquiries regarding its operational protocols.
The milestone was confirmed by the company, which stated the procedure was completed without complication and the patient is recovering satisfactorily. The implant, known as the ‘Link,’ is designed to interpret neural signals, initially aiming to empower individuals with quadriplegia to control external digital devices through thought alone.
This second implantation follows the initial procedure on the first participant, Noland Arbaugh, earlier this year. The company’s ambitious roadmap extends beyond medical applications, with long-term visions of facilitating seamless human-computer symbiosis.
Concurrent with this medical advancement, Neuralink remains under examination by the U.S. Department of Transportation (DOT). The investigation focuses on potential compliance lapses in the transportation of hazardous materials, specifically related to the movement of implanted hardware. A separate inquiry by the U.S. Food and Drug Administration (FDA) is reviewing the company’s adherence to standard record-keeping practices for animal testing. Neuralink has publicly committed to full cooperation with all federal agencies, emphasizing its dedication to safety and regulatory compliance.